Cochrane · systematic review · CD006643

Interferon Beta for Primary Progressive Multiple Sclerosis

Rojas, JI, Romano, M, Ciapponi, A, et al. · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library

Multiple Sclerosis and Rare Diseases of the CNS2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 5 · 100%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Comparison

Population: patients with Primary Progressive Multiple Sclerosis

CD006643.PUB3 (current) · 5 questions

Outcome	Effect	Evidence	Status / GRADE
Patients with progression of the disease (	RR 0.89 [0.55, 1.43]	2 studies · 123 participants	High
Patients with severe adverse event (	RR 0.8 [0.33, 1.92]	1 study · 73 participants	High
Patients with any related adverse event (	RR 1.9 [1.45, 2.48]	2 studies · 123 participants	High
Mean EDSS change at two years (	no estimate extracted	1 study · 73 participants	High
Sustained increase in spasticity (	RR 0.56 [0.32, 1]	1 study · 50 participants	High

Comparison

Population: patients with Primary Progressive Multiple Sclerosis

CD006643.PUB2 · 5 questions

Outcome	Effect	Evidence	Status / GRADE
Patients with progression of the disease (	RR 0.89 [0.55, 1.43]	2 studies · 123 participants	High
Patients with severe adverse event (	RR 0.8 [0.33, 1.92]	1 study · 73 participants	High
Patients with any related adverse event (	RR 1.9 [1.45, 2.48]	2 studies · 123 participants	High
Mean EDSS change at two years (	no estimate extracted	1 study · 73 participants	High
Sustained increase in spasticity (	RR 0.56 [0.32, 1]	1 study · 50 participants	High